You are here: Home: LCU 4 | 2006 : Thomas E Stinchcombe, MD: Select publications

SELECT PUBLICATIONS

Gradishar WJ et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23(31):7794-803. Abstract

Green MR et al. Abraxane®, a novel Cremophor® -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17(8):1263-8. Abstract

Hawkins MJ et al. Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2006;Abstract 7132.

Herbst RS, Sandler AB. Non-small cell lung cancer and antiangiogenic therapy: What can be expected of bevacizumab? Oncologist 2004;9(Suppl 1):19-26. Abstract

Sandler AB et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): An Eastern Cooperative Oncology Group (ECOG) Trial — E4599. Proc ASCO 2005;Abstract 4.

Sparreboom A et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005;11(11):4136-43. Abstract

Stinchcombe TE et al. Preliminary results of phase I trial of carboplatin (CP) in combination with ABI-007 administered weekly or every 3 weeks in patients (pts) with solid tumors. San Antonio Breast Cancer Symposium 2005;Abstract 1092.

Table of Contents

Top of Page